125 related articles for article (PubMed ID: 12067545)
1. Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability.
Borthwick AD; Exall AM; Haley TM; Jackson DL; Mason AM; Weingarten GG
Bioorg Med Chem Lett; 2002 Jul; 12(13):1719-22. PubMed ID: 12067545
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.
Borthwick AD; Davies DE; Ertl PF; Exall AM; Haley TM; Hart GJ; Jackson DL; Parry NR; Patikis A; Trivedi N; Weingarten GG; Woolven JM
J Med Chem; 2003 Oct; 46(21):4428-49. PubMed ID: 14521407
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality.
Borthwick AD; Crame AJ; Ertl PF; Exall AM; Haley TM; Hart GJ; Mason AM; Pennell AM; Singh OM; Weingarten GG; Woolven JM
J Med Chem; 2002 Jan; 45(1):1-18. PubMed ID: 11754575
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
Slater MJ; Amphlett EM; Andrews DM; Bamborough P; Carey SJ; Johnson MR; Jones PS; Mills G; Parry NR; Somers DO; Stewart AJ; Skarzynski T
Org Lett; 2003 Nov; 5(24):4627-30. PubMed ID: 14627400
[TBL] [Abstract][Full Text] [Related]
5. From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.
Gerona-Navarro G; Pérez de Vega MJ; García-López MT; Andrei G; Snoeck R; De Clercq E; Balzarini J; González-Muñiz R
J Med Chem; 2005 Apr; 48(7):2612-21. PubMed ID: 15801851
[TBL] [Abstract][Full Text] [Related]
6. Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease.
Andrews DM; Barnes MC; Dowle MD; Hind SL; Johnson MR; Jones PS; Mills G; Patikis A; Pateman TJ; Redfern TJ; Robinson JE; Slater MJ; Trivedi N
Org Lett; 2003 Nov; 5(24):4631-4. PubMed ID: 14627401
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 1. The alpha-methyl-trans-lactam template.
Borthwick AD; Angier SJ; Crame AJ; Exall AM; Haley TM; Hart GJ; Mason AM; Pennell AM; Weingarten GG
J Med Chem; 2000 Nov; 43(23):4452-64. PubMed ID: 11087570
[TBL] [Abstract][Full Text] [Related]
8. Design of translactam HCMV protease inhibitors as potent antivirals.
Borthwick AD
Med Res Rev; 2005 Jul; 25(4):427-52. PubMed ID: 15789440
[TBL] [Abstract][Full Text] [Related]
9. Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.
Andrews DM; Carey SJ; Chaignot H; Coomber BA; Gray NM; Hind SL; Jones PS; Mills G; Robinson JE; Slater MJ
Org Lett; 2002 Dec; 4(25):4475-8. PubMed ID: 12465916
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.
Slater MJ; Andrews DM; Baker G; Bethell SS; Carey S; Chaignot H; Clarke B; Coomber B; Ellis M; Good A; Gray N; Hardy G; Jones P; Mills G; Robinson E
Bioorg Med Chem Lett; 2002 Dec; 12(23):3359-62. PubMed ID: 12419361
[TBL] [Abstract][Full Text] [Related]
11. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
Nair LG; Sannigrahi M; Bogen S; Pinto P; Chen KX; Prongay A; Tong X; Cheng KC; Girijavallabhan V; George Njoroge F
Bioorg Med Chem Lett; 2010 Jan; 20(2):567-70. PubMed ID: 20004570
[TBL] [Abstract][Full Text] [Related]
12. Advances in matrix metalloproteinase inhibitors based on pyrrolidine scaffold.
Cheng XC; Wang Q; Fang H; Xu WF
Curr Med Chem; 2008; 15(4):374-85. PubMed ID: 18288992
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antiviral activity of monobactams inhibiting the human cytomegalovirus protease.
Ogilvie WW; Yoakim C; Dô F; Haché B; Lagacé L; Naud J; O'Meara JA; Déziel R
Bioorg Med Chem; 1999 Aug; 7(8):1521-31. PubMed ID: 10482444
[TBL] [Abstract][Full Text] [Related]
14. Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332.
Pavan M; Bolcato G; Bassani D; Sturlese M; Moro S
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1646-1650. PubMed ID: 34289752
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.
Andrews DM; Jones PS; Mills G; Hind SL; Slater MJ; Trivedi N; Wareing KJ
Bioorg Med Chem Lett; 2003 May; 13(10):1657-60. PubMed ID: 12729635
[TBL] [Abstract][Full Text] [Related]
16. Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituents.
Andrews DM; Chaignot H; Coomber BA; Good AC; Hind SL; Johnson MR; Jones PS; Mills G; Robinson JE; Skarzynski T; Slater MJ; Somers DO
Org Lett; 2002 Dec; 4(25):4479-82. PubMed ID: 12465917
[TBL] [Abstract][Full Text] [Related]
17. Recent strategies in the development of new human cytomegalovirus inhibitors.
Martinez A; Castro A; Gil C; Perez C
Med Res Rev; 2001 May; 21(3):227-44. PubMed ID: 11301412
[TBL] [Abstract][Full Text] [Related]
18. The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease.
Flynn DL; Becker DP; Dilworth VM; Highkin MK; Hippenmeyer PJ; Houseman KA; Levine LM; Li M; Moormann AE; Rankin A; Toth MV; Villamil CI; Wittwer AJ; Holwerda BC
Drug Des Discov; 1997 May; 15(1):3-15. PubMed ID: 9332827
[TBL] [Abstract][Full Text] [Related]
19. Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors.
Chung V; Carroll AR; Gray NM; Parry NR; Thommes PA; Viner KC; D'Souza EA
Antimicrob Agents Chemother; 2005 Apr; 49(4):1381-90. PubMed ID: 15793116
[TBL] [Abstract][Full Text] [Related]
20. Intracellular inhibition of human neutrophil elastase by orally active pyrrolidine-trans-lactams.
Macdonald SJ; Dowle MD; Harrison LA; Spooner JE; Shah P; Johnson MR; Inglis GG; Clarke GD; Belton DJ; Smith RA; Molloy CR; Dixon M; Murkitt G; Godward RE; Skarzynski T; Singh OM; Kumar KA; Hodgson ST; McDonald E; Hardy GW; Finch H; Humphreys DC; Fleetwood G
Bioorg Med Chem Lett; 2001 Jan; 11(2):243-6. PubMed ID: 11206469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
